Search Results

REALM IDx, Inc., a health care company pioneering the field of integrated diagnostics, announced that GenMineTOP Cancer Genome Profiling System has been awarded national health coverage in Japan and will begin full commercial launch of contract testing with strategic partner, LSI Medicine Corporation.

REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced their companies’ selection by the University of California, Irvine and the GREGoR Consortium to support the Pediatric Mendelian Genomics Research Center program to better understand the underlying biology of rare diseases.

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling.

Digital Diagnostics, a leading artificial intelligence (AI) diagnostic healthcare company’s flagship product, LumineticsCore™ (formerly IDx-DR), is increasing access to innovative care at OSF HealthCare for people living with diabetes.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

REALM IDx, Inc., a leader in integrated diagnostics, announced the company will participate in the upcoming 40th Annual J.P. Morgan Health Care Conference.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics annual meeting results of a study published in JAMA Oncology that assessed the cumulative impact of paired DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants of uncertain significance.

Konica Minolta Precision Medicine (KMPM), a majority-owned subsidiary of Konica Minolta, Inc., announced today that it has changed its name to REALM IDx, Inc.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system